This is where we have to pump the brakes. Those headline numbers are eye-catching, but when you dig into the data, you find some serious reasons for caution. The first major red flag is the study’s discontinuation rate.
An astonishing 18% of participants on the higher dose of Retatrutide dropped out of the study before it was finished. To put that in perspective, the dropout rate in the Ozempic trial was 4.5%, and in the Mounjaro trial, it was just over 7%. An 18% dropout rate is extraordinarily high and suggests that for nearly one in five people, the experience of taking the drug was intolerable.
The study authors suggest this was because people with a lower starting BMI dropped out after losing “too much weight.” But even if you only look at people with a higher BMI, the rate was still over 12%—much higher than its competitors. This high rate was likely driven by adverse effects.
All these drugs share common side effects like nausea and diarrhea. With Retatrutide, about 35% of participants reported diarrhea, compared to 23% with Mounjaro. But the most worrying side effect is one that is very rare with the other drugs: dysesthesia. This is a nerve condition where you experience unpleasant sensations like pain, itching, burning, or tingling when your skin is touched. In the Mounjaro studies, only 0.4% of people reported this. In the Retatrutide study, almost 21% of people on the high dose reported it. Even though the researchers said the symptoms were mild, this is a massive red flag that needs serious investigation.
5. A Statistical Sleight of Hand? Why 29% Isn’t the Whole Story
There’s another crucial detail buried in the study’s preliminary report. The 28.7% weight loss figure comes from what’s called an “efficacy estimate.” This analysis essentially shows the best-case scenario, estimating the drug’s effect if everyone followed the study protocol perfectly and no one dropped out.
However, a more realistic measure is the “treatment regimen estimate” (also known as an intention-to-treat analysis). This includes everyone who started the study, giving a better picture of the real-world impact. When you look at this number for Retatrutide, the average weight loss at the highest dose was 23.7%.
Now, let’s compare that to Mounjaro’s real-world number, which was 20.9%. Suddenly, the massive gap between the two drugs shrinks dramatically. The difference is no longer a whopping 8 percentage points (29% vs. 21%), but a much smaller 2.8 percentage points (23.7% vs. 20.9%).
My Take: Is Retatrutide Worth the Risk?
So, let’s return to our original question. What’s the catch? The catch is that you’re trading a significantly higher risk of side effects—including a 1-in-5 chance of developing a painful skin condition—for a potential extra 3% of weight loss compared to the next best option.
For most people, that is not a good trade-off. Until we have much more long-term safety data, I would not consider Retatrutide a first-line option over a drug like Mounjaro/Zepbound (Tirzepatide), which appears to have a much better balance of effectiveness and tolerability.
Retatrutide might eventually find its place as an option for people who don’t achieve their goals on other medications and are willing to accept the higher risk profile. But for now, it’s a powerful tool with some very sharp edges.
Conclusion
Retatrutide represents the cutting edge of weight loss science, and its power is undeniable. However, power always comes with responsibility and risk. The headlines are shouting about 29% weight loss, but the full story is far more complex. It involves concerning side effects, high dropout rates, and nuanced statistics. While it’s an exciting development to watch, for now, the best approach is one of cautious optimism. We must wait for the full, peer-reviewed data to be published before we can truly know if the benefits of this powerful new drug outweigh its considerable costs.
Source: Dr. Brad Stanfield
